Autoimmune diseases and atherosclerotic cardiovascular disease.

Journal

Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075

Informations de publication

Date de publication:
27 Jun 2024
Historique:
accepted: 28 05 2024
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 27 6 2024
Statut: aheadofprint

Résumé

Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have been implicated in mediating the autoimmunity-associated cardiovascular risk, either directly or by modulating the effect of other risk factors in a complex interplay. Aberrant leukocyte function and pro-inflammatory cytokines are central to both disease entities, resulting in vascular dysfunction, impaired resolution of inflammation and promotion of chronic inflammation. Similarly, loss of tolerance to self-antigens and the generation of autoantibodies are key features of autoimmunity but are also implicated in the maladaptive inflammatory response during atherosclerotic cardiovascular disease. Therefore, immunomodulatory therapies are potential efficacious interventions to directly reduce the risk of cardiovascular disease, and biomarkers of autoimmune disease activity could be relevant tools to stratify patients with autoimmunity according to their cardiovascular risk. In this Review, we discuss the pathophysiological aspects of the increased cardiovascular risk associated with autoimmunity and highlight the many open questions that need to be answered to develop novel therapies that specifically address this unmet clinical need.

Identifiants

DOI: 10.1038/s41569-024-01045-7 PMID: 38937626
pubmed: 38937626
doi: 10.1038/s41569-024-01045-7
pii: 10.1038/s41569-024-01045-7
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Springer Nature Limited.

Références

Ridker, P. M. et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 401, 1293–1301 (2023).
pubmed: 36893777 doi: 10.1016/S0140-6736(23)00215-5
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
pubmed: 28845751 doi: 10.1056/NEJMoa1707914
Fiolet, A. T. L. et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur. Heart J. 42, 2765–2775 (2021).
pubmed: 33769515 doi: 10.1093/eurheartj/ehab115
Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021).
pubmed: 33883728 doi: 10.1038/s41586-021-03392-8
Byrne, R. A. et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur. Heart J. Acute Cardiovasc 44, 3720–3826 (2023).
doi: 10.1093/eurheartj/ehad191
Ridker, P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ. Res. 118, 145–156 (2016).
pubmed: 26837745 pmcid: 4793711 doi: 10.1161/CIRCRESAHA.115.306656
Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. Nat. Rev. Cardiol. 17, 387–401 (2020).
pubmed: 32203286 pmcid: 7872210 doi: 10.1038/s41569-020-0352-5
Porsch, F., Mallat, Z. & Binder, C. J. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc. Res. 117, 2544–2562 (2021).
pubmed: 34450620
Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251–265 (2022).
pubmed: 34389841 doi: 10.1038/s41577-021-00584-1
Mallat, Z. & Binder, C. J. The why and how of adaptive immune responses in ischemic cardiovascular disease. Nat. Cardiovasc. Res. 1, 431–444 (2022).
pubmed: 36382200 pmcid: 7613798 doi: 10.1038/s44161-022-00049-1
Conrad, N. et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400, 733–743 (2022).
pubmed: 36041475 doi: 10.1016/S0140-6736(22)01349-6
Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim. 4, 18001 (2018).
pubmed: 29417936 doi: 10.1038/nrdp.2018.1
Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2, 16039 (2016).
pubmed: 27306639 doi: 10.1038/nrdp.2016.39
Skaggs, B. J., Hahn, B. H. & McMahon, M. Accelerated atherosclerosis in patients with SLE – mechanisms and management. Nat. Rev. Rheumatol. 8, 214–223 (2012).
pubmed: 22331061 pmcid: 3765069 doi: 10.1038/nrrheum.2012.14
Ambler, W. G. & Kaplan, M. J. Vascular damage in systemic lupus erythematosus. Nat. Rev. Nephrol. 20, 251–265 (2024).
pubmed: 38172627 doi: 10.1038/s41581-023-00797-8
Weber, B. N., Giles, J. T. & Liao, K. P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat. Rev. Rheumatol. 19, 417–428 (2023).
pubmed: 37231248 doi: 10.1038/s41584-023-00969-7
Forte, F. et al. Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies. Rheumatology 59, 3181–3192 (2020).
pubmed: 32793980 doi: 10.1093/rheumatology/keaa414
Restivo, V. et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun. Rev. 21, 102925 (2022).
pubmed: 34454117 doi: 10.1016/j.autrev.2021.102925
Yafasova, A. et al. Long-term cardiovascular outcomes in systemic lupus erythematosus. J. Am. Coll. Cardiol. 77, 1717–1727 (2021).
pubmed: 33832598 doi: 10.1016/j.jacc.2021.02.029
Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408–415 (1997).
pubmed: 9048514 doi: 10.1093/oxfordjournals.aje.a009122
Sparks, J. A. et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health Study. Arthritis Care Res 68, 753–762 (2016).
doi: 10.1002/acr.22752
Bartoloni, E. et al. Cardiovascular disease risk burden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study. J. Intern. Med. 278, 185–192 (2015).
pubmed: 25582881 doi: 10.1111/joim.12346
Butt, S. A. et al. Cardiovascular manifestations of systemic sclerosis: a Danish nationwide cohort study. J. Am. Heart Assoc. 8, e013405 (2019).
pubmed: 31446827 pmcid: 6755829 doi: 10.1161/JAHA.119.013405
Kiani, A. N. Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. Rheumatology 54, 1976–1981 (2015).
pubmed: 26106213 pmcid: 4715250 doi: 10.1093/rheumatology/kev198
Carlucci, P. M. et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight 3, e99276 (2018).
pubmed: 29669944 pmcid: 5931124 doi: 10.1172/jci.insight.99276
Agca, R. et al. Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis. Rheumatology 60, 3360–3368 (2021).
pubmed: 33447846 pmcid: 8516502 doi: 10.1093/rheumatology/keaa789
Geraldino-Pardilla, L. et al. Arterial inflammation detected with
pubmed: 28992382 doi: 10.1002/art.40345
Hansen, P. R., Feineis, M. & Abdulla, J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: a systematic literature review and meta-analysis. Eur. J. Intern. Med. 62, 72–79 (2019).
pubmed: 30826172 doi: 10.1016/j.ejim.2019.02.018
Tyrrell, P. N. et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 30, 1014–1026 (2010).
pubmed: 20150560 doi: 10.1161/ATVBAHA.109.198424
Willeit, P. et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation 142, 621–642 (2020).
pubmed: 32546049 pmcid: 7115957 doi: 10.1161/CIRCULATIONAHA.120.046361
Gautier, E. L. et al. Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler. Thromb. Vasc. Biol. 27, 1625–1631 (2007).
pubmed: 17446440 doi: 10.1161/ATVBAHA.107.142430
Aprahamian, T. et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199, 1121–1131 (2004).
pubmed: 15096538 pmcid: 2211887 doi: 10.1084/jem.20031557
Ma, Z. et al. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin. Immunol. 127, 168–175 (2008).
pubmed: 18325838 pmcid: 2464279 doi: 10.1016/j.clim.2008.01.002
Feng, X. et al. ApoE
pubmed: 17259598 doi: 10.1194/jlr.M600512-JLR200
Lewis, M. J. et al. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum. 64, 2707–2718 (2012).
pubmed: 22392450 pmcid: 3607248 doi: 10.1002/art.34451
Stanic, A. K. et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 103, 7018–7023 (2006).
pubmed: 16636270 pmcid: 1459011 doi: 10.1073/pnas.0602311103
Braun, N. A., Wade, N. S., Wakeland, E. K. & Major, A. S. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr
pubmed: 19029274 pmcid: 2662384 doi: 10.1177/0961203308093551
Wilhelm, A. J., Rhoads, J. P., Wade, N. S. & Major, A. S. Dysregulated CD4
pubmed: 24395554 doi: 10.1136/annrheumdis-2013-203759
Postigo, J. et al. Exacerbation of type II collagen-induced arthritis in apolipoprotein E-deficient mice in association with the expansion of Th1 and Th17 cells. Arthritis Rheum. 63, 971–980 (2011).
pubmed: 21225684 doi: 10.1002/art.30220
Shi, N. et al. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Anim. Models Exp. Med. 2, 98–106 (2019).
doi: 10.1002/ame2.12065
Santiago-Raber, M.-L. et al. Atherosclerotic plaque vulnerability is increased in mouse model of lupus. Sci. Rep. 10, 18324 (2020).
pubmed: 33110193 pmcid: 7591560 doi: 10.1038/s41598-020-74579-8
Centa, M. et al. Acute loss of apolipoprotein E triggers an autoimmune response that accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 38, e145–e158 (2018).
pubmed: 29880490 pmcid: 6173285 doi: 10.1161/ATVBAHA.118.310802
Hutchinson, M. A. et al. Auto-antibody production during experimental atherosclerosis in ApoE
pubmed: 34305930 pmcid: 8299997 doi: 10.3389/fimmu.2021.695220
Ryu, H. et al. Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27. Nat. Immunol. 19, 583–593 (2018).
pubmed: 29713015 doi: 10.1038/s41590-018-0102-6
Afek, A. et al. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 67, 19–25 (1999).
pubmed: 9873224 doi: 10.1159/000028046
Wang, X. et al. Anti-β
pubmed: 30871774 doi: 10.1016/j.bbrc.2019.03.020
Nicolo, D., Goldman, B. I. & Monestier, M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum. 48, 2974–2978 (2003).
pubmed: 14558104 doi: 10.1002/art.11255
Rose, S. et al. A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis. Ann. Rheum. Dis. 72, 89–95 (2013).
pubmed: 22736097 doi: 10.1136/annrheumdis-2012-201431
Archer, A. M. et al. ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model. J. Transl. Med. 14, 170 (2016).
pubmed: 27287704 pmcid: 4901400 doi: 10.1186/s12967-016-0912-y
Dragoljevic, D. et al. Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis. Eur. Heart J. 39, 2158–2167 (2018).
pubmed: 29905812 pmcid: 6001889 doi: 10.1093/eurheartj/ehy119
Timmis, A. et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur. Heart J. 43, 716–799 (2022).
pubmed: 35016208 doi: 10.1093/eurheartj/ehab892
Hermansen, M.-L. et al. Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. Rheumatology 57, 1964–1971 (2018).
pubmed: 30016488 doi: 10.1093/rheumatology/key201
Robinson, G., Pineda-Torra, I., Ciurtin, C. & Jury, E. C. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J. Clin. Invest. 132, e148552 (2022).
pubmed: 35040437 pmcid: 8759788 doi: 10.1172/JCI148552
Takvorian, S. U., Merola, J. F. & Costenbader, K. H. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 23, 537–544 (2014).
pubmed: 24763538 doi: 10.1177/0961203313501400
Maisha, J. A., El-Gabalawy, H. S. & O’Neil, L. J. Modifiable risk factors linked to the development of rheumatoid arthritis: evidence, immunological mechanisms and prevention. Front. Immunol. 14, 1221125 (2023).
pubmed: 37767100 pmcid: 10520718 doi: 10.3389/fimmu.2023.1221125
Szabó, M. Z., Szodoray, P. & Kiss, E. Dyslipidemia in systemic lupus erythematosus. Immunol. Res. 65, 543–550 (2017).
pubmed: 28168401 doi: 10.1007/s12026-016-8892-9
Purmalek, M. M. et al. Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE. Lupus Sci. Med. 6, e000332 (2019).
pubmed: 31413851 pmcid: 6667837 doi: 10.1136/lupus-2019-000332
Ramos-Casals, M. et al. High prevalence of serum metabolic alterations in primary Sjögren’s syndrome: influence on clinical and immunological expression. J. Rheumatol. 34, 754–761 (2007).
pubmed: 17309127
Kronbichler, A., Leierer, J., Gauckler, P. & Shin, J. I. Comorbidities in ANCA-associated vasculitis. Rheumatology 59, iii79–iii83 (2020).
pubmed: 32348518 pmcid: 7190116 doi: 10.1093/rheumatology/kez617
McMahon, M. et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 2541–2549 (2006).
pubmed: 16868975 doi: 10.1002/art.21976
Charles-Schoeman, C. et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 60, 2870–2879 (2009).
pubmed: 19790070 pmcid: 2828490 doi: 10.1002/art.24802
Smith, C. K. et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. 66, 2532–2544 (2014).
pubmed: 24838349 pmcid: 4146708 doi: 10.1002/art.38703
Charles-Schoeman, C. et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin. Arthritis Rheum. 46, 71–80 (2016).
pubmed: 27079757 doi: 10.1016/j.semarthrit.2016.03.004
Yan, J. et al. Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Front. Immunol. 14, 1254753 (2023).
pubmed: 37954591 pmcid: 10634280 doi: 10.3389/fimmu.2023.1254753
Turesson, C., Bergström, U., Pikwer, M., Nilsson, J.-Å. & Jacobsson, L. T. High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study. Arthritis Res. Ther. 17, 284 (2015).
pubmed: 26458977 pmcid: 4603637 doi: 10.1186/s13075-015-0804-1
Wang, M. et al. The causal relationship between blood lipids and systemic lupus erythematosus risk: a bidirectional two-sample Mendelian randomization study. Front. Genet. 13, 858653 (2022).
pubmed: 35495122 pmcid: 9043646 doi: 10.3389/fgene.2022.858653
Kawai, V. K. et al. Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: a phenome-wide association study and inverse-variance weighted meta-analysis. Lupus 30, 1264–1272 (2021).
pubmed: 33977795 pmcid: 8205989 doi: 10.1177/09612033211014952
Schloss, M. J., Swirski, F. K. & Nahrendorf, M. Modifiable cardiovascular risk, hematopoiesis and innate immunity. Circ. Res. 126, 1242–1259 (2020).
pubmed: 32324501 pmcid: 7185037 doi: 10.1161/CIRCRESAHA.120.315936
Jury, E. C., Isenberg, D. A., Mauri, C. & Ehrenstein, M. R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 177, 7416–7422 (2006).
pubmed: 17082661 doi: 10.4049/jimmunol.177.10.7416
Krishnan, S. et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J. Immunol. 172, 7821–7831 (2004).
pubmed: 15187166 doi: 10.4049/jimmunol.172.12.7821
Baardman, J. & Lutgens, E. Regulatory T cell metabolism in atherosclerosis. Metabolites 10, 279 (2020).
pubmed: 32650487 pmcid: 7408402 doi: 10.3390/metabo10070279
Maganto-García, E., Tarrio, M. L., Grabie, N., Bu, D. & Lichtman, A. H. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 124, 185–195 (2011).
pubmed: 21690490 pmcid: 3145407 doi: 10.1161/CIRCULATIONAHA.110.006411
Gaddis, D. E. et al. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat. Commun. 9, 1095 (2018).
pubmed: 29545616 pmcid: 5854619 doi: 10.1038/s41467-018-03493-5
Klingenberg, R. et al. Depletion of FOXP3
pubmed: 23426179 pmcid: 3582120 doi: 10.1172/JCI63891
Wang, Z. et al. Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis. Nat. Cardiovasc. Res. 2, 290–306 (2023).
pubmed: 37621765 pmcid: 10448629 doi: 10.1038/s44161-023-00218-w
Khan, A., Roy, P. & Ley, K. Breaking tolerance: the autoimmune aspect of atherosclerosis. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-024-01010-y (2024).
Ito, A. et al. Cholesterol accumulation in CD11c
pubmed: 28002731 pmcid: 5181791 doi: 10.1016/j.immuni.2016.11.008
Westerterp, M. et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 25, 1294–1304.e6 (2017).
pubmed: 28479366 pmcid: 5514787 doi: 10.1016/j.cmet.2017.04.005
Rahman, P., Aguero, S., Gladman, D. D., Hallett, D. & Urowitz, M. B. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 9, 672–675 (2000).
pubmed: 11199921 doi: 10.1191/096120300669204787
Bartoloni, E., Alunno, A. & Gerli, R. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat. Rev. Cardiol. 15, 33–44 (2018).
pubmed: 28836617 doi: 10.1038/nrcardio.2017.118
Costello, R. E., Yimer, B. B., Roads, P., Jani, M. & Dixon, W. G. Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology 60, 132–139 (2021).
pubmed: 32596721 doi: 10.1093/rheumatology/keaa209
Mathis, K. W. et al. Preventing autoimmunity protects against the development of hypertension and renal injury. Hypertension 64, 792–800 (2014).
pubmed: 25024282 doi: 10.1161/HYPERTENSIONAHA.114.04006
McClung, D. M., Kalusche, W. J., Jones, K. E., Ryan, M. J. & Taylor, E. B. Hypertension and endothelial dysfunction in the pristane model of systemic lupus erythematosus. Physiol. Rep. 9, e14734 (2021).
pubmed: 33527772 pmcid: 7851437 doi: 10.14814/phy2.14734
Zhang, K. et al. Rheumatoid arthritis and the risk of major cardiometabolic diseases: a Mendelian randomization study. Scand. J. Rheumatol. 52, 335–341 (2023).
pubmed: 35658786 doi: 10.1080/03009742.2022.2070988
Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31–55 (2022).
pubmed: 35021057 pmcid: 8773457 doi: 10.1016/j.immuni.2021.12.013
Haase, C. L., Tybjærg-Hansen, A., Nordestgaard, B. G. & Frikke-Schmidt, R. HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes 64, 3328–3333 (2015).
pubmed: 25972569 doi: 10.2337/db14-1603
Mellor, D. D. et al. Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study. Nutr. Metab. Cardiovasc. Dis. 30, 788–795 (2020).
pubmed: 32127339 doi: 10.1016/j.numecd.2020.01.008
Peng, J. et al. Association between dyslipidemia and risk of type 2 diabetes mellitus in middle-aged and older Chinese adults: a secondary analysis of a nationwide cohort. BMJ Open 11, e042821 (2021).
pubmed: 34035089 pmcid: 8154929 doi: 10.1136/bmjopen-2020-042821
de Resende Guimarães, M. F. B. et al. High prevalence of obesity in rheumatoid arthritis patients: association with disease activity. hypertension, dyslipidemia and diabetes, a multi-center study. Adv. Rheumatol. 59, 44 (2019).
pubmed: 31619287 doi: 10.1186/s42358-019-0089-1
Tamargo, I. A., Baek, K. I., Kim, Y., Park, C. & Jo, H. Flow-induced reprogramming of endothelial cells in atherosclerosis. Nat. Rev. Cardiol. 20, 738–753 (2023).
pubmed: 37225873 doi: 10.1038/s41569-023-00883-1
Gimbrone, M. A. & García-Cardeña, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118, 620–636 (2016).
pubmed: 26892962 pmcid: 4762052 doi: 10.1161/CIRCRESAHA.115.306301
Bordy, R. et al. Microvascular endothelial dysfunction in rheumatoid arthritis. Nat. Rev. Rheumatol. 14, 404–420 (2018).
pubmed: 29855620 doi: 10.1038/s41584-018-0022-8
Matucci-Cerinic, M., Kahaleh, B. & Wigley, F. M. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 65, 1953–1962 (2013).
pubmed: 23666787 doi: 10.1002/art.37988
Weber, B. N. et al. Coronary microvascular dysfunction in systemic lupus erythematosus. J. Am. Heart Assoc. 10, e018555 (2021).
pubmed: 34132099 pmcid: 8403317 doi: 10.1161/JAHA.120.018555
Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).
pubmed: 37156255 doi: 10.1016/S0140-6736(23)00457-9
Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 15002 (2015).
pubmed: 27189141 doi: 10.1038/nrdp.2015.2
Libby, P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J. Am. Coll. Cardiol. 70, 2278–2289 (2017).
pubmed: 29073957 pmcid: 5687846 doi: 10.1016/j.jacc.2017.09.028
Chen, H.-J., Tas, S. W. & de Winther, M. P. J. Type-I interferons in atherosclerosis. J. Exp. Med. 217, e20190459 (2020).
pubmed: 31821440 doi: 10.1084/jem.20190459
Urschel, K. & Cicha, I. TNF-α in the cardiovascular system: from physiology to therapy. Int. J. Interferon Cytokine Mediat. Res. 7, 9–25 (2015).
Buie, J. J., Renaud, L. L., Muise-Helmericks, R. & Oates, J. C. IFN-α negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus. J. Immunol. 199, 1979–1988 (2017).
pubmed: 28779021 doi: 10.4049/jimmunol.1600108
Akhmedov, A. et al. TNFα induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFα antibodies. Cardiovasc. Res. 118, 254–266 (2022).
pubmed: 33483748 doi: 10.1093/cvr/cvab005
Mak, A. et al. Endothelial dysfunction in systemic lupus erythematosus – a case-control study and an updated meta-analysis and meta-regression. Sci. Rep. 7, 7320 (2017).
pubmed: 28779080 pmcid: 5544707 doi: 10.1038/s41598-017-07574-1
Denny, M. F. et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184, 3284–3297 (2010).
pubmed: 20164424 doi: 10.4049/jimmunol.0902199
Denny, M. F. et al. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110, 2907–2915 (2007).
pubmed: 17638846 pmcid: 2018671 doi: 10.1182/blood-2007-05-089086
Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538–552 (2011).
pubmed: 21613614 doi: 10.4049/jimmunol.1100450
Carmona-Rivera, C., Zhao, W., Yalavarthi, S. & Kaplan, M. J. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann. Rheum. Dis. 74, 1417–1424 (2015).
pubmed: 24570026 doi: 10.1136/annrheumdis-2013-204837
Rajagopalan, S. et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103, 3677–3683 (2004).
pubmed: 14726373 doi: 10.1182/blood-2003-09-3198
Lee, P. Y. et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 56, 3759–3769 (2007).
pubmed: 17968925 doi: 10.1002/art.23035
Pieterse, E. et al. Neutrophil extracellular traps drive endothelial-to-mesenchymal transition. Arterioscler. Thromb. Vasc. Biol. 37, 1371–1379 (2017).
pubmed: 28495931 doi: 10.1161/ATVBAHA.117.309002
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625 (2009).
pubmed: 19448636 pmcid: 2760083 doi: 10.1038/nm.1959
Schreiber, A. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc. Natl Acad. Sci. USA 114, E9618–E9625 (2017).
pubmed: 29078325 pmcid: 5692554 doi: 10.1073/pnas.1708247114
Nakazawa, D., Masuda, S., Tomaru, U. & Ishizu, A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat. Rev. Rheumatol. 15, 91–101 (2019).
pubmed: 30542206 doi: 10.1038/s41584-018-0145-y
Lood, C. et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 116, 1951–1957 (2010).
pubmed: 20538795 doi: 10.1182/blood-2010-03-274605
Nhek, S. et al. Activated platelets induce endothelial cell activation via an interleukin-1β pathway in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 37, 707–716 (2017).
pubmed: 28153882 pmcid: 5597960 doi: 10.1161/ATVBAHA.116.308126
Maugeri, N. et al. Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis. Sci. Transl. Med. 10, eaao3089 (2018).
pubmed: 30045975 doi: 10.1126/scitranslmed.aao3089
Legendre, P., Régent, A., Thiebault, M. & Mouthon, L. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun. Rev. 16, 146–153 (2017).
pubmed: 27989761 doi: 10.1016/j.autrev.2016.12.012
Truchetet, M. E., Brembilla, N. C. & Chizzolini, C. Current concepts on the pathogenesis of systemic sclerosis. Clin. Rev. Allergy Immunol. 64, 262–283 (2023).
pubmed: 34487318 doi: 10.1007/s12016-021-08889-8
Almanzar, G. et al. Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions. J. Autoimmun. 39, 441–450 (2012).
pubmed: 22901435 pmcid: 3516706 doi: 10.1016/j.jaut.2012.07.006
Crane, E. D. et al. Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions. JCI Insight 3, e99363 (2018).
pubmed: 30568038 pmcid: 6338388 doi: 10.1172/jci.insight.99363
Ait-Oufella, H., Taleb, S., Mallat, Z. & Tedgui, A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 969–979 (2011).
pubmed: 21508343 doi: 10.1161/ATVBAHA.110.207415
Ait-Oufella, H., Libby, P. & Tedgui, A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 39, 1510–1519 (2019).
pubmed: 31294625 pmcid: 6681658 doi: 10.1161/ATVBAHA.119.311998
Shin, J. I. et al. Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review. J. Autoimmun. 103, 102299 (2019).
pubmed: 31326231 doi: 10.1016/j.jaut.2019.06.010
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).
pubmed: 28104796 pmcid: 5542057 doi: 10.1126/science.aag1381
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
pubmed: 33731931 pmcid: 8038646 doi: 10.1038/s41586-021-03341-5
Svensson, E. C. et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 7, 521–528 (2022).
pubmed: 35385050 pmcid: 8988022 doi: 10.1001/jamacardio.2022.0386
David, C. et al. Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology 61, 4355–4363 (2022).
pubmed: 35176141 doi: 10.1093/rheumatology/keac108
Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448–463 (2022).
pubmed: 35729334 pmcid: 9210802 doi: 10.1038/s41584-022-00797-1
Clark, W., Jobanputra, P., Barton, P. & Burls, A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol. Assess. 8, 18 (2004).
doi: 10.3310/hta8180
Schiff, M. H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59, i103–i108 (2000).
pubmed: 11053099 pmcid: 1766616 doi: 10.1136/ard.59.suppl_1.i103
Eastgate, J. A. et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2, 706–709 (1988).
pubmed: 2901567 doi: 10.1016/S0140-6736(88)90185-7
McGeachy, M. J. et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat. Immunol. 8, 1390–1397 (2007).
pubmed: 17994024 doi: 10.1038/ni1539
Zhou, L. et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).
pubmed: 17581537 doi: 10.1038/ni1488
Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 128, 1728–1746 (2021).
pubmed: 33998272 doi: 10.1161/CIRCRESAHA.121.319077
van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ. Res. 122, 433–443 (2018).
pubmed: 29212778 pmcid: 5805277 doi: 10.1161/CIRCRESAHA.117.312086
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214–1224 (2012).
doi: 10.1016/S0140-6736(12)60110-X
Sarwar, N. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).
pubmed: 22421339 doi: 10.1016/S0140-6736(11)61931-4
Rosa, M. et al. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. NPJ Genom. Med 4, 23 (2019).
pubmed: 31552141 pmcid: 6754413 doi: 10.1038/s41525-019-0097-4
Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124–131 (2020).
pubmed: 31707836 doi: 10.1161/CIRCULATIONAHA.119.044362
Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Heart J. 39, 3499–3507 (2018).
pubmed: 30165610 doi: 10.1093/eurheartj/ehy310
Romano, M. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6, 315–325 (1997).
pubmed: 9075932 doi: 10.1016/S1074-7613(00)80334-9
Alsaffar, H., Martino, N., Garrett, J. P. & Adam, A. P. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am. J. Physiol. Cell Physiol. 314, C589–C602 (2018).
pubmed: 29351406 doi: 10.1152/ajpcell.00235.2017
Neumann, F.-J. et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. 17, 3399–3405 (1997).
pubmed: 9437185 doi: 10.1161/01.ATV.17.12.3399
Holt, I., Cooper, R. G. & Hopkins, S. J. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur. J. Clin. Invest. 21, 479–484 (1991).
pubmed: 1752286 doi: 10.1111/j.1365-2362.1991.tb01398.x
Marczynski, P. et al. Vascular inflammation and dysfunction in lupus-prone mice-IL-6 as mediator of disease initiation. Int. J. Mol. Sci. 22, 2291 (2021).
pubmed: 33669022 pmcid: 7956579 doi: 10.3390/ijms22052291
Weber, B. et al. Relationship between risk of atherosclerotic cardiovascular disease, inflammation, and coronary microvascular dysfunction in rheumatoid arthritis. J. Am. Heart Assoc. 11, e025467 (2022).
pubmed: 35657008 pmcid: 9238711 doi: 10.1161/JAHA.121.025467
Bacchiega, B. C. et al. Interleukin 6 inhibition and coronary artery disease in a high‐risk population: a prospective community‐based clinical study. J. Am. Heart Assoc. 6, e005038 (2017).
pubmed: 28288972 pmcid: 5524026 doi: 10.1161/JAHA.116.005038
Protogerou, A. D. et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219, 734–736 (2011).
pubmed: 21968316 doi: 10.1016/j.atherosclerosis.2011.09.015
Souto, A. et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 67, 117–127 (2015).
pubmed: 25303044 doi: 10.1002/art.38894
McInnes, I. B. et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 74, 694–702 (2015).
pubmed: 24368514 doi: 10.1136/annrheumdis-2013-204345
Pierini, F. S. et al. Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. an observational study. Rheumatol. Ther. 8, 803–815 (2021).
pubmed: 33811316 pmcid: 8217399 doi: 10.1007/s40744-021-00304-0
Giles, J. T. et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 72, 31–40 (2020).
pubmed: 31469238 doi: 10.1002/art.41095
Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060–2069 (2021).
pubmed: 34015342 doi: 10.1016/S0140-6736(21)00520-1
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT05021835 (2024).
van Loo, G. & Bertrand, M. J. M. Death by TNF: a road to inflammation. Nat. Rev. Immunol. 23, 289–303 (2023).
pubmed: 36380021 doi: 10.1038/s41577-022-00792-3
Siegmund, D. & Wajant, H. TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nat. Rev. Rheumatol. 19, 576–591 (2023).
pubmed: 37542139 doi: 10.1038/s41584-023-01002-7
Weckerle, C. E. et al. Large scale analysis of tumor necrosis factor ɑ levels in systemic lupus erythematosus. Arthritis Rheum. 64, 2947–2952 (2012).
pubmed: 22488302 pmcid: 3396783 doi: 10.1002/art.34483
Rho, Y. H. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 61, 1580–1585 (2009).
pubmed: 19877084 pmcid: 2828265 doi: 10.1002/art.25009
Del Porto, F. et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 46, 1111–1115 (2007).
pubmed: 17449484 doi: 10.1093/rheumatology/kem089
Papamichail, G. V. et al. The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study. Heart Vessels 37, 2128–2136 (2022).
pubmed: 35739432 doi: 10.1007/s00380-022-02114-y
Jacobsson, L. T. H. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005).
pubmed: 15996054
Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor ɑ therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
pubmed: 17763428 pmcid: 2435427 doi: 10.1002/art.22809
Barnabe, C., Martin, B.-J. & Ghali, W. A. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63, 522–529 (2011).
doi: 10.1002/acr.20371
Roubille, C. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 480–489 (2015).
pubmed: 25561362 doi: 10.1136/annrheumdis-2014-206624
McKellar, G. E., McCarey, D. W., Sattar, N. & McInnes, I. B. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 6, 410–417 (2009).
pubmed: 19421244 doi: 10.1038/nrcardio.2009.57
Ridker, P. M. et al. Elevation of tumor necrosis factor-ɑ and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149–2153 (2000).
pubmed: 10801754 doi: 10.1161/01.CIR.101.18.2149
Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-ɑ, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
pubmed: 12796126 doi: 10.1161/01.CIR.0000077913.60364.D2
Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594–1602 (2004).
pubmed: 15023878 doi: 10.1161/01.CIR.0000124490.27666.B2
Solomon, D. H. et al. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Ann. Rheum. Dis. 82, 324–330 (2023).
pubmed: 36450449 doi: 10.1136/ard-2022-223302
Goossens, P. et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 12, 142–153 (2010).
pubmed: 20674859 doi: 10.1016/j.cmet.2010.06.008
Li, J. et al. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum. 63, 492–502 (2011).
pubmed: 21280004 doi: 10.1002/art.30165
Boshuizen, M. C. S. et al. Interferon-β promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine 77, 220–226 (2016).
pubmed: 26427927 doi: 10.1016/j.cyto.2015.09.016
Pulliam, L., Calosing, C., Sun, B., Grunfeld, C. & Rempel, H. Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS production. J. Interferon Cytokine Res. 34, 822–828 (2014).
pubmed: 24731171 pmcid: 4186262 doi: 10.1089/jir.2013.0152
Spann, N. J. et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 151, 138–152 (2012).
pubmed: 23021221 pmcid: 3464914 doi: 10.1016/j.cell.2012.06.054
Kim, K. et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ. Res. 123, 1127–1142 (2018).
pubmed: 30359200 pmcid: 6945121 doi: 10.1161/CIRCRESAHA.118.312804
Zernecke, A. et al. Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. Cardiovasc. Res. 119, 1676–1689 (2023).
pubmed: 36190844 doi: 10.1093/cvr/cvac161
King, K. R. et al. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat. Med. 23, 1481–1487 (2017).
pubmed: 29106401 pmcid: 6477926 doi: 10.1038/nm.4428
Lin, J.-D. et al. Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stem-like properties, during atherosclerosis progression and regression. JCI Insight 4, e124574 (2019).
pubmed: 30830865 pmcid: 6478411 doi: 10.1172/jci.insight.124574
Park, S. H. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104–1116 (2017).
pubmed: 28825701 pmcid: 5605457 doi: 10.1038/ni.3818
Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213–223 (2011).
pubmed: 21349431 doi: 10.1016/j.immuni.2011.02.006
Reboldi, A. et al. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345, 679–684 (2014).
pubmed: 25104388 pmcid: 4289637 doi: 10.1126/science.1254790
Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574–1583 (2019).
pubmed: 31745335 pmcid: 7024546 doi: 10.1038/s41590-019-0466-2
Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146–153 (2016).
pubmed: 26779811 pmcid: 4742415 doi: 10.1038/nm.4027
Lövgren, T., Eloranta, M.-L., Båve, U., Alm, G. V. & Rönnblom, L. Induction of interferon-ɑ production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861–1872 (2004).
pubmed: 15188363 doi: 10.1002/art.20254
Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582–3586 (2007).
pubmed: 18034431 doi: 10.1002/eji.200737815
Sisirak, V. et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166, 88–101 (2016).
pubmed: 27293190 pmcid: 5030815 doi: 10.1016/j.cell.2016.05.034
Caielli, S. et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J. Exp. Med. 213, 697–713 (2016).
pubmed: 27091841 pmcid: 4854735 doi: 10.1084/jem.20151876
Blanco, L. P. et al. RNA externalized by neutrophil extracellular traps promotes inflammatory pathways in endothelial cells. Arthritis Rheumatol. 73, 2282–2292 (2021).
pubmed: 33983685 pmcid: 8589882 doi: 10.1002/art.41796
Bellini, R., Bonacina, F. & Norata, G. D. Crosstalk between dendritic cells and T lymphocytes during atherogenesis: focus on antigen presentation and break of tolerance. Front. Cardiovasc. Med. 9, 934314 (2022).
pubmed: 35966516 pmcid: 9365967 doi: 10.3389/fcvm.2022.934314
Nagahama, M. et al. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity 33, 85–94 (2001).
pubmed: 11264787 doi: 10.3109/08916930108995993
Duffau, P. et al. Platelet CD154 potentiates interferon-ɑ secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med. 2, 47ra63 (2010).
pubmed: 20811042 doi: 10.1126/scitranslmed.3001001
Massberg, S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196, 887–896 (2002).
pubmed: 12370251 pmcid: 2194025 doi: 10.1084/jem.20012044
Huo, Y. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9, 61–67 (2003).
pubmed: 12483207 doi: 10.1038/nm810
Barrett, T. J. et al. Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis. Sci. Transl. Med. 11, eaax0481 (2019).
pubmed: 31694925 pmcid: 6905432 doi: 10.1126/scitranslmed.aax0481
Crow, M. K. & Wohlgemuth, J. Microarray analysis of gene expression in lupus. Arthritis Res Ther. 5, 279 (2003).
pubmed: 14680503 pmcid: 333417 doi: 10.1186/ar1015
Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902–914 (2019).
pubmed: 31209404 pmcid: 6726437 doi: 10.1038/s41590-019-0398-x
Eloranta, M.-L. et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann. Rheum. Dis. 69, 1396–1402 (2010).
pubmed: 20472592 doi: 10.1136/ard.2009.121400
van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433–443 (2014).
pubmed: 24350901 doi: 10.1056/NEJMoa1114576
Gottenberg, J.-E. et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc. Natl Acad. Sci. USA 103, 2770–2775 (2006).
pubmed: 16477017 pmcid: 1413808 doi: 10.1073/pnas.0510837103
Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 14, 214–228 (2018).
pubmed: 29559718 pmcid: 6625751 doi: 10.1038/nrrheum.2018.31
Somers, E. C. et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PloS ONE 7, e37000 (2012).
pubmed: 22606325 pmcid: 3351452 doi: 10.1371/journal.pone.0037000
Rogacev, K. S. et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J. Am. Coll. Cardiol. 60, 1512–1520 (2012).
pubmed: 22999728 doi: 10.1016/j.jacc.2012.07.019
Lioté, F., Boval-Boizard, B., Weill, D., Kuntz, D. & Wautier, J. L. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. Clin. Exp. Immunol. 106, 13–19 (1996).
pubmed: 8870692 pmcid: 2200557 doi: 10.1046/j.1365-2249.1996.d01-820.x
Rossol, M., Kraus, S., Pierer, M., Baerwald, C. & Wagner, U. The CD14
pubmed: 22006178 doi: 10.1002/art.33418
Korman, B. D. et al. Inflammatory expression profiles in monocyte-to-macrophage differentiation in patients with systemic lupus erythematosus and relationship with atherosclerosis. Arthritis Res. Ther. 16, R147 (2014).
pubmed: 25011540 pmcid: 4227297 doi: 10.1186/ar4609
O’Gorman, W. E. et al. Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J. Allergy Clin. Immunol. 136, 1326–1336 (2015).
pubmed: 26037552 pmcid: 4640970 doi: 10.1016/j.jaci.2015.04.008
Shi, L. et al. Monocyte enhancers are highly altered in systemic lupus erythematosus. Epigenomics 7, 921–935 (2015).
pubmed: 26442457 pmcid: 4864065 doi: 10.2217/epi.15.47
Mikołajczyk, T. P. et al. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 25, 18–27 (2016).
pubmed: 26251402 doi: 10.1177/0961203315598014
López, P. et al. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology 59, 1752–1764 (2020).
pubmed: 32031658 doi: 10.1093/rheumatology/keaa016
Tacke, F. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 185–194 (2007).
pubmed: 17200718 pmcid: 1716202 doi: 10.1172/JCI28549
Combadière, C. et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C
pubmed: 18347211 doi: 10.1161/CIRCULATIONAHA.107.745091
Adamstein, N. H. et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur. Heart J. 42, 896–903 (2021).
pubmed: 33417682 pmcid: 7936519 doi: 10.1093/eurheartj/ehaa1034
Nurmohamed, N. S. et al. Targeted proteomics improves cardiovascular risk prediction in secondary prevention. Eur. Heart J. 43, 1569–1577 (2022).
pubmed: 35139537 pmcid: 9020984 doi: 10.1093/eurheartj/ehac055
Luo, J., Thomassen, J. Q., Nordestgaard, B. G., Tybjærg-Hansen, A. & Frikke-Schmidt, R. Neutrophil counts and cardiovascular disease. Eur. Heart J. 44, 4953–4964 (2023).
pubmed: 37950632 pmcid: 10719495 doi: 10.1093/eurheartj/ehad649
Zernecke, A. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 102, 209–217 (2008).
pubmed: 17991882 doi: 10.1161/CIRCRESAHA.107.160697
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C. & Soehnlein, O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122, 1837–1845 (2010).
pubmed: 20956207 doi: 10.1161/CIRCULATIONAHA.110.961714
Delporte, C. et al. Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100. J. Lipid Res. 55, 747–757 (2014).
pubmed: 24534704 pmcid: 3966708 doi: 10.1194/jlr.M047449
Döring, Y. et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ. Res. 110, 1052–1056 (2012).
pubmed: 22394519 doi: 10.1161/CIRCRESAHA.112.265868
Nakamura, Y. et al. Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis. J. Clin. Invest. 134, e172578 (2024).
pubmed: 38194294 pmcid: 10904043 doi: 10.1172/JCI172578
Knight, J. S. et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ. Res. 114, 947–956 (2014).
pubmed: 24425713 pmcid: 4185401 doi: 10.1161/CIRCRESAHA.114.303312
Quillard, T. et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur. Heart J. 36, 1394–1404 (2015).
pubmed: 25755115 pmcid: 4458287 doi: 10.1093/eurheartj/ehv044
Silvestre-Roig, C. et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature 569, 236–240 (2019).
pubmed: 31043745 pmcid: 6716525 doi: 10.1038/s41586-019-1167-6
Mangold, A. et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ. Res. 116, 1182–1192 (2015).
pubmed: 25547404 doi: 10.1161/CIRCRESAHA.116.304944
Libby, P., Pasterkamp, G., Crea, F. & Jang, I.-K. Reassessing the mechanisms of acute coronary syndromes. Circ. Res. 124, 150–160 (2019).
pubmed: 30605419 pmcid: 6447371 doi: 10.1161/CIRCRESAHA.118.311098
Gómez-Moreno, D., Adrover, J. M. & Hidalgo, A. Neutrophils as effectors of vascular inflammation. Eur. J. Clin. Invest. 48, e12940 (2018).
pubmed: 29682731 doi: 10.1111/eci.12940
Franck, G. et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice. Circ. Res. 121, 31–42 (2017).
pubmed: 28428204 pmcid: 5488735 doi: 10.1161/CIRCRESAHA.117.310694
Franck, G. et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury. Circ. Res. 123, 33–42 (2018).
pubmed: 29572206 pmcid: 6014872 doi: 10.1161/CIRCRESAHA.117.312494
Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. USA 107, 15880–15885 (2010).
pubmed: 20798043 pmcid: 2936604 doi: 10.1073/pnas.1005743107
Folco, E. J. et al. Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1α and cathepsin G. Arterioscler. Thromb. Vasc. Biol. 38, 1901–1912 (2018).
pubmed: 29976772 pmcid: 6202190 doi: 10.1161/ATVBAHA.118.311150
Ferrante, G. et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes. Circulation 122, 2505–2513 (2010).
pubmed: 21126969 doi: 10.1161/CIRCULATIONAHA.110.955302
Apel, F., Zychlinsky, A. & Kenny, E. F. The role of neutrophil extracellular traps in rheumatic diseases. Nat. Rev. Rheumatol. 14, 467–475 (2018).
pubmed: 29930301 doi: 10.1038/s41584-018-0039-z
Wigerblad, G. & Kaplan, M. J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. 23, 274–288 (2023).
pubmed: 36257987 doi: 10.1038/s41577-022-00787-0
Wipke, B. T. & Allen, P. M. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167, 1601–1608 (2001).
pubmed: 11466382 doi: 10.4049/jimmunol.167.3.1601
Grieshaber-Bouyer, R. et al. Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint. Ann. Rheum. Dis. 81, 805–814 (2022).
pubmed: 35168946 doi: 10.1136/annrheumdis-2021-221866
Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).
pubmed: 21389264 pmcid: 3143837 doi: 10.1126/scitranslmed.3001201
Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011).
pubmed: 21389263 pmcid: 3399524 doi: 10.1126/scitranslmed.3001180
Döring, Y. et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 125, 1673–1683 (2012).
pubmed: 22388324 doi: 10.1161/CIRCULATIONAHA.111.046755
Rahman, S. et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann. Rheum. Dis. 78, 957–966 (2019).
pubmed: 31040119 doi: 10.1136/annrheumdis-2018-214620
Kiss, M. G. & Binder, C. J. The multifaceted impact of complement on atherosclerosis. Atherosclerosis 351, 29–40 (2022).
pubmed: 35365353 doi: 10.1016/j.atherosclerosis.2022.03.014
Stark, K. & Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 18, 666–682 (2021).
pubmed: 33958774 pmcid: 8100938 doi: 10.1038/s41569-021-00552-1
Seifert, P. S., Hugo, F., Hansson, G. K. & Bhakdi, S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. 60, 747–754 (1989).
pubmed: 2659887
Vlaicu, R., Rus, H. G., Niculescu, F. & Cristea, A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55, 35–50 (1985).
pubmed: 2408631 doi: 10.1016/0021-9150(85)90164-9
Kiss, M. G. et al. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Immunity 56, 1809–1824.e10 (2023).
pubmed: 37499656 doi: 10.1016/j.immuni.2023.06.026
Truedsson, L., Bengtsson, A. A. & Sturfelt, G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40, 560–566 (2007).
pubmed: 18075790 doi: 10.1080/08916930701510673
Stojan, G. & Petri, M. Anti-C1q in systemic lupus erythematosus. Lupus 25, 873–877 (2016).
pubmed: 27252264 pmcid: 7523495 doi: 10.1177/0961203316645205
Dragon-Durey, M.-A., Blanc, C., Marinozzi, M. C., van Schaarenburg, R. A. & Trouw, L. A. Autoantibodies against complement components and functional consequences. Mol. Immunol. 56, 213–221 (2013).
pubmed: 23790637 doi: 10.1016/j.molimm.2013.05.009
Santer, D. M. et al. C1q deficiency leads to the defective suppression of IFN-ɑ in response to nucleoprotein containing immune complexes. J. Immunol. 185, 4738–4749 (2010).
pubmed: 20844193 doi: 10.4049/jimmunol.1001731
Coss, S. L. et al. The complement system and human autoimmune diseases. J. Autoimmun. 137, 102979 (2023).
pubmed: 36535812 doi: 10.1016/j.jaut.2022.102979
Aringer, M. et al. 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400–1412 (2019).
pubmed: 31385462 pmcid: 6827566 doi: 10.1002/art.40930
Chen, M., Jayne, D. R. W. & Zhao, M.-H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359–367 (2017).
pubmed: 28316335 doi: 10.1038/nrneph.2017.37
Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576–1588 (2019).
pubmed: 31591603 pmcid: 7318784 doi: 10.1038/s41591-019-0590-4
Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178–180 (2006).
pubmed: 16462800 doi: 10.1038/nm1343
Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127, 335–353 (2020).
pubmed: 32336197 pmcid: 7367765 doi: 10.1161/CIRCRESAHA.119.316461
Rosetti, F., Madera-Salcedo, I. K., Rodríguez-Rodríguez, N. & Crispín, J. C. Regulation of activated T cell survival in rheumatic autoimmune diseases. Nat. Rev. Rheumatol. 18, 232–244 (2022).
pubmed: 35075294 doi: 10.1038/s41584-021-00741-9
Sumida, T. S., Cheru, N. T. & Hafler, D. A. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-024-00994-x (2024).
Kolios, A. G. A., Tsokos, G. C. & Klatzmann, D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat. Rev. Rheumatol. 17, 749–766 (2021).
pubmed: 34728817 doi: 10.1038/s41584-021-00707-x
Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949–962 (2013).
pubmed: 24238343 pmcid: 3912996 doi: 10.1016/j.immuni.2013.10.016
Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277–285 (2004).
pubmed: 15280421 pmcid: 2211983 doi: 10.1084/jem.20040165
Komatsu, N. et al. Pathogenic conversion of Foxp3
pubmed: 24362934 doi: 10.1038/nm.3432
Li, J. et al. CCR5
pubmed: 27021296 pmcid: 4867125 doi: 10.1161/CIRCRESAHA.116.308648
Butcher, M. J. et al. Atherosclerosis-driven treg plasticity results in formation of a dysfunctional subset of plastic IFNγ
pubmed: 27635087 pmcid: 5242312 doi: 10.1161/CIRCRESAHA.116.309764
Kimura, T. et al. Regulatory CD4
pubmed: 29588316 pmcid: 6160361 doi: 10.1161/CIRCULATIONAHA.117.031420
Spee-Mayer et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407–1415 (2016).
doi: 10.1136/annrheumdis-2015-207776
He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4
pubmed: 27500725 doi: 10.1038/nm.4148
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).
pubmed: 30472651 doi: 10.1136/annrheumdis-2018-214229
He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141–149 (2020).
pubmed: 31537547 doi: 10.1136/annrheumdis-2019-215396
Akbarzadeh, R., Riemekasten, G. & Humrich, J. Y. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus. Curr. Opin. Rheumatol. 35, 98–106 (2023).
pubmed: 36563007 doi: 10.1097/BOR.0000000000000924
Sriranjan, R. et al. Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. BMJ Open 12, e062602 (2022).
pubmed: 36207050 pmcid: 9558794 doi: 10.1136/bmjopen-2022-062602
Koshy, M., Berger, D. & Crow, M. K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98, 826–837 (1996).
pubmed: 8698875 pmcid: 507493 doi: 10.1172/JCI118855
Liossis, S. N., Ding, X. Z., Dennis, G. J. & Tsokos, G. C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest. 101, 1448–1457 (1998).
pubmed: 9525988 pmcid: 508723 doi: 10.1172/JCI1457
Enyedy, E. J. et al. Fcϵ receptor type I γ chain replaces the deficient T cell receptor ζ chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 44, 1114–1121 (2001).
pubmed: 11352243 doi: 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B
Wagner, U. G., Koetz, K., Weyand, C. M. & Goronzy, J. J. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 95, 14447–14452 (1998).
pubmed: 9826720 pmcid: 24393 doi: 10.1073/pnas.95.24.14447
Weyand, C. M. & Goronzy, J. J. The immunology of rheumatoid arthritis. Nat. Immunol. 22, 10–18 (2021).
pubmed: 33257900 doi: 10.1038/s41590-020-00816-x
Weng, N., Akbar, A. N. & Goronzy, J. CD28
pubmed: 19540809 pmcid: 2801888 doi: 10.1016/j.it.2009.03.013
Dumitriu, I. E. et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4
pubmed: 22282196 doi: 10.1161/CIRCRESAHA.111.261933
Liuzzo, G. et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101, 2883–2888 (2000).
pubmed: 10869258 doi: 10.1161/01.CIR.101.25.2883
Téo, F. H. et al. Characterization of CD4
pubmed: 23416719 doi: 10.1016/j.cellimm.2013.01.007
Okba, A. M. et al. Expanded peripheral CD4
pubmed: 30853362 doi: 10.1016/j.humimm.2019.03.008
Gerli, R. et al. CD4
pubmed: 15159291 doi: 10.1161/01.CIR.0000131450.66017.B3
Jiang, Q. et al. Role of Th22 cells in the pathogenesis of autoimmune diseases. Front. Immunol. 12, 688066 (2021).
pubmed: 34295334 pmcid: 8290841 doi: 10.3389/fimmu.2021.688066
Schnell, A., Littman, D. R. & Kuchroo, V. K. TH17 cell heterogeneity and its role in tissue inflammation. Nat. Immunol. 24, 19–29 (2023).
pubmed: 36596896 pmcid: 10795475 doi: 10.1038/s41590-022-01387-9
Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62, 234–244 (2010).
pubmed: 20039395 doi: 10.1002/art.25032
Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110–114 (2017).
pubmed: 28150777 pmcid: 5349321 doi: 10.1038/nature20810
Nus, M. et al. Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet. Nat. Med. 23, 601–610 (2017).
pubmed: 28414328 doi: 10.1038/nm.4315
Clement, M. et al. Control of the T follicular helper–germinal center B-cell axis by CD8
pubmed: 25552357 doi: 10.1161/CIRCULATIONAHA.114.010988
Bocharnikov, A. V. et al. PD-1
pubmed: 31536480 pmcid: 6824311 doi: 10.1172/jci.insight.130062
Hu, D. et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin β receptors. Immunity 42, 1100–1115 (2015).
pubmed: 26084025 pmcid: 4678289 doi: 10.1016/j.immuni.2015.05.015
Srikakulapu, P. et al. Artery tertiary lymphoid organs control multilayered territorialized atherosclerosis B-cell responses in aged ApoE
pubmed: 27102965 pmcid: 4894775 doi: 10.1161/ATVBAHA.115.306983
Paulsson, G., Zhou, X., Törnquist, E. & Hansson, G. K. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20, 10–17 (2000).
pubmed: 10634795 doi: 10.1161/01.ATV.20.1.10
Lin, Z. et al. Deep sequencing of the T cell receptor β repertoire reveals signature patterns and clonal drift in atherosclerotic plaques and patients. Oncotarget 8, 99312–99322 (2017).
pubmed: 29245903 pmcid: 5725094 doi: 10.18632/oncotarget.19892
Sage, A. P., Tsiantoulas, D., Binder, C. J. & Mallat, Z. The role of B cells in atherosclerosis. Nat. Rev. Cardiol. 16, 180–196 (2019).
pubmed: 30410107 doi: 10.1038/s41569-018-0106-9
Chaturvedi, A., Dorward, D. & Pierce, S. K. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 28, 799–809 (2008).
pubmed: 18513998 pmcid: 2601674 doi: 10.1016/j.immuni.2008.03.019
Groom, J. R. et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204, 1959–1971 (2007).
pubmed: 17664289 pmcid: 2118661 doi: 10.1084/jem.20062567
Rubtsov, A. V. et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c
pubmed: 21543762 pmcid: 3152497 doi: 10.1182/blood-2011-01-331462
Naradikian, M. S. et al. Cutting edge: IL-4, IL-21, and IFN-γ interact to govern T-bet and CD11c expression in TLR-activated B cells. J. Immunol. 197, 1023–1028 (2016).
pubmed: 27430719 doi: 10.4049/jimmunol.1600522
Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349–356 (2022).
pubmed: 35477763 pmcid: 9095492 doi: 10.1038/s41586-022-04642-z
Guerrier, T., Youinou, P., Pers, J.-O. & Jamin, C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J. Autoimmun. 39, 173–179 (2012).
pubmed: 22695187 doi: 10.1016/j.jaut.2012.05.012
Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).
pubmed: 12920303 doi: 10.1126/science.1086907
Dörner, T., Jacobi, A. M., Lee, J. & Lipsky, P. E. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 363, 187–197 (2011).
pubmed: 20598709 doi: 10.1016/j.jim.2010.06.009
Meeuwsen, J. A. L. et al. High levels of (un)switched memory B cells are associated with better outcome in patients with advanced atherosclerotic disease. J. Am. Heart Assoc. 6, e005747 (2017).
pubmed: 28882820 pmcid: 5634255 doi: 10.1161/JAHA.117.005747
She, Z. et al. The role of B1 cells in systemic lupus erythematosus. Front. Immunol. 13, 814857 (2022).
pubmed: 35418972 pmcid: 8995743 doi: 10.3389/fimmu.2022.814857
Mantovani, L., Wilder, R. L. & Casali, P. Human rheumatoid B-1a (CD5
pubmed: 7686945 doi: 10.4049/jimmunol.151.1.473
Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl Acad. Sci. USA 99, 5545–5550 (2002).
pubmed: 11960012 pmcid: 122806 doi: 10.1073/pnas.082114899
Rubtsova, K. et al. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J. Clin. Invest. 127, 1392–1404 (2017).
pubmed: 28240602 pmcid: 5373868 doi: 10.1172/JCI91250
Buono, C. et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl Acad. Sci. USA 102, 1596–1601 (2005).
pubmed: 15665085 pmcid: 547865 doi: 10.1073/pnas.0409015102
Li, Z.-Y., Cai, M.-L., Qin, Y. & Chen, Z. Age/autoimmunity-associated B cells in inflammatory arthritis: an emerging therapeutic target. Front. Immunol. 14, 1103307 (2023).
pubmed: 36817481 pmcid: 9933781 doi: 10.3389/fimmu.2023.1103307
Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928–942 (2019).
pubmed: 31061532 pmcid: 6602051 doi: 10.1038/s41590-019-0378-1
Qin, Y. et al. Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways. Ann. Rheum. Dis. 81, 1504–1514 (2022).
pubmed: 35760450 doi: 10.1136/ard-2022-222605
Smit, V. et al. Single-cell profiling reveals age-associated immunity in atherosclerosis. Cardiovasc. Res. 119, 2508–2521 (2023).
pubmed: 37390467 pmcid: 10676459 doi: 10.1093/cvr/cvad099
Ait-Oufella, H. et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 207, 1579–1587 (2010).
pubmed: 20603314 pmcid: 2916123 doi: 10.1084/jem.20100155
Kyaw, T. et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J. Immunol. 185, 4410–4419 (2010).
pubmed: 20817865 doi: 10.4049/jimmunol.1000033
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT05211401 (2023).
Giordano, D. et al. B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease. Front. Immunol. 14, 1050528 (2023).
pubmed: 36923413 pmcid: 10009188 doi: 10.3389/fimmu.2023.1050528
Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).
pubmed: 15189742 doi: 10.1016/j.immuni.2004.05.010
Hamilton, J. A., Hsu, H.-C. & Mountz, J. D. Autoreactive B cells in SLE, villains or innocent bystanders? Immunol. Rev. 292, 120–138 (2019).
pubmed: 31631359 pmcid: 6935412 doi: 10.1111/imr.12815
Zhang, J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166, 6–10 (2001).
pubmed: 11123269 doi: 10.4049/jimmunol.166.1.6
Salazar-Camarena, D. C. et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 25, 582–592 (2016).
pubmed: 26424128 doi: 10.1177/0961203315608254
Stohl, W. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475–3486 (2003).
pubmed: 14673998 doi: 10.1002/art.11354
Landolt-Marticorena, C. et al. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J. Rheumatol. 38, 642–651 (2011).
pubmed: 21239754 doi: 10.3899/jrheum.100214
Sage, A. P. et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice – brief report. Arterioscler. Thromb. Vasc. Biol. 32, 1573–1576 (2012).
pubmed: 22426131 doi: 10.1161/ATVBAHA.111.244731
Kyaw, T. et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PloS ONE 7, e29371 (2012).
pubmed: 22238605 pmcid: 3251583 doi: 10.1371/journal.pone.0029371
Jackson, S. W. et al. Cutting edge: BAFF overexpression reduces atherosclerosis via TACI-dependent B cell activation. J. Immunol. 197, 4529–4534 (2016).
pubmed: 27837104 doi: 10.4049/jimmunol.1601198
Tsiantoulas, D. et al. B cell-activating factor neutralization aggravates atherosclerosis. Circulation 138, 2263–2273 (2018).
pubmed: 29858401 pmcid: 6181204 doi: 10.1161/CIRCULATIONAHA.117.032790
Saidoune, F. et al. Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus. Arthritis Rheumatol. 73, 255–264 (2021).
pubmed: 32783382 doi: 10.1002/art.41485
Mauri, C. & Blair, P. A. Regulatory B cells in autoimmunity: developments and controversies. Nat. Rev. Rheumatol. 6, 636–643 (2010).
pubmed: 20856268 doi: 10.1038/nrrheum.2010.140
Sakkas, L. I., Daoussis, D., Mavropoulos, A., Liossis, S.-N. & Bogdanos, D. P. Regulatory B cells: new players in inflammatory and autoimmune rheumatic diseases. Semin. Arthritis Rheum. 48, 1133–1141 (2019).
pubmed: 30409417 doi: 10.1016/j.semarthrit.2018.10.007
Meng, X. et al. Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat. Commun. 9, 251 (2018).
pubmed: 29343683 pmcid: 5772476 doi: 10.1038/s41467-017-02683-x
Gao, N. et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol. 66, 2849–2861 (2014).
pubmed: 24942956 doi: 10.1002/art.38742
Smith, K. G. C. & Clatworthy, M. R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328–343 (2010).
pubmed: 20414206 pmcid: 4148599 doi: 10.1038/nri2762
Bagchi-Chakraborty, J. et al. B cell Fcγ receptor IIb modulates atherosclerosis in male and female mice by controlling adaptive germinal center and innate B-1-cell responses. Arterioscler. Thromb. Vasc. Biol. 39, 1379–1389 (2019).
pubmed: 31092015 pmcid: 6636804 doi: 10.1161/ATVBAHA.118.312272
Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509–524 (2023).
pubmed: 37165096 doi: 10.1038/s41581-023-00720-1
Lewis, M. J. et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor–deficient mice. Circulation 120, 417–426 (2009).
pubmed: 19620499 pmcid: 2761224 doi: 10.1161/CIRCULATIONAHA.109.868158
Tsiantoulas, D. et al. Increased plasma IgE accelerate atherosclerosis in secreted IgM deficiency. Circ. Res. 120, 78–84 (2017).
pubmed: 27903567 doi: 10.1161/CIRCRESAHA.116.309606
Ebrahimian, T. et al. B cell-specific knockout of AID protects against atherosclerosis. Sci. Rep. 13, 8723 (2023).
pubmed: 37253865 pmcid: 10229602 doi: 10.1038/s41598-023-35980-1
Centa, M. et al. Germinal center-derived antibodies promote atherosclerosis plaque size and stability. Circulation 139, 2466–2482 (2019).
pubmed: 30894016 doi: 10.1161/CIRCULATIONAHA.118.038534
Tay, C. et al. Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G. Arterioscler. Thromb. Vasc. Biol. 38, e71–e84 (2018).
pubmed: 29599140 doi: 10.1161/ATVBAHA.117.310678
Mackey, R. H. et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the Women’s Health Initiative. Arthritis Rheumatol. 67, 2311–2322 (2015).
pubmed: 25988241 pmcid: 4551571 doi: 10.1002/art.39198
Hörkkö, S. et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98, 815–825 (1996).
pubmed: 8698874 pmcid: 507492 doi: 10.1172/JCI118854
Deroissart, J. & Binder, C. J. Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 20, 433–434 (2023).
pubmed: 37169831 doi: 10.1038/s41569-023-00888-w
Grönwall, C. et al. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin. Immunol. 142, 390–398 (2012).
pubmed: 22297166 pmcid: 3632049 doi: 10.1016/j.clim.2012.01.002
Thiagarajan, D. et al. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Sci. Rep. 10, 11010 (2020).
pubmed: 32620913 pmcid: 7335044 doi: 10.1038/s41598-020-66981-z
Anania, C. et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res. Ther. 12, R214 (2010).
pubmed: 21092251 pmcid: 3046524 doi: 10.1186/ar3193
Shaw, P. X. et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105, 1731–1740 (2000).
pubmed: 10862788 pmcid: 378505 doi: 10.1172/JCI8472
Binder, C. J. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9, 736–743 (2003).
pubmed: 12740573 doi: 10.1038/nm876
Chen, Y. et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183, 1346–1359 (2009).
pubmed: 19564341 doi: 10.4049/jimmunol.0900948
Faria-Neto, J. R. et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189, 83–90 (2006).
pubmed: 16386745 doi: 10.1016/j.atherosclerosis.2005.11.033
Urowitz, M. B., Ibañez, D., Su, J. & Gladman, D. D. Modified Framingham Risk Factor Score for systemic lupus erythematosus. J. Rheumatol. 43, 875–879 (2016).
pubmed: 26879352 doi: 10.3899/jrheum.150983
Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357, j2099 (2017).
pubmed: 28536104 pmcid: 5441081 doi: 10.1136/bmj.j2099
Petri, M. A., Barr, E. & Magder, L. S. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Sci. Med. 6, e000346 (2019).
pubmed: 31749976 pmcid: 6827738 doi: 10.1136/lupus-2019-000346
McMahon, M. et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol. 66, 130–139 (2014).
pubmed: 24449580 pmcid: 4106468 doi: 10.1002/art.38204
Skaggs, B. J. et al. A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol. 3, 209–220 (2021).
pubmed: 33605563 pmcid: 8063147 doi: 10.1002/acr2.11223
Sivakumaran, J. et al. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci. Med. 8, e000448 (2021).
pubmed: 34045359 pmcid: 8162102 doi: 10.1136/lupus-2020-000448
Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).
pubmed: 27697765 doi: 10.1136/annrheumdis-2016-209775
Drosos, G. C. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 81, 768–779 (2022).
pubmed: 35110331 doi: 10.1136/annrheumdis-2021-221733
Buckley, L. F. & Libby, P. Colchicine’s role in cardiovascular disease management. Arterioscler. Thromb. Vasc. Biol. 44, 1031–1041 (2024).
pubmed: 38511324 doi: 10.1161/ATVBAHA.124.319851
Wade, N. S., Stevenson, B. G., Dunlap, D. S. & Major, A. S. The lupus susceptibility locus Sle3 is not sufficient to accelerate atherosclerosis in lupus-susceptible low density lipoprotein receptor-deficient mice. Lupus 19, 34–42 (2010).
pubmed: 19850656 doi: 10.1177/0961203309345785
Asquith, D. L. et al. Apolipoprotein E-deficient mice are resistant to the development of collagen-induced arthritis. Arthritis Rheum. 62, 472–477 (2010).
pubmed: 20112375 doi: 10.1002/art.27205
Blackler, G. et al. The effect of HLA-DRB1*04:01 on a mouse model of atherosclerosis. J. Transl. Autoimmun. 7, 100203 (2023).
pubmed: 37408614 pmcid: 10318502 doi: 10.1016/j.jtauto.2023.100203
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
pubmed: 30415610 doi: 10.1056/NEJMoa1809798
Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
pubmed: 31733140 doi: 10.1056/NEJMoa1912388
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404–410 (2013).
pubmed: 23265346 doi: 10.1016/j.jacc.2012.10.027
Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020).
pubmed: 32865380 doi: 10.1056/NEJMoa2021372
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT03048825 (2024).
Kelly, P. et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet https://doi.org/10.1016/S0140-6736(24)00968-1 (2024).
doi: 10.1016/S0140-6736(24)00968-1 pubmed: 38857611
Morton, A. C. et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur. Heart J. 36, 377–384 (2015).
pubmed: 25079365 doi: 10.1093/eurheartj/ehu272
Abbate, A. et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). Am. J. Cardiol. 105, 1371–1377.e1 (2010).
pubmed: 20451681 doi: 10.1016/j.amjcard.2009.12.059
Abbate, A. et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University–Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111, 1394–1400 (2013).
pubmed: 23453459 pmcid: 3644511 doi: 10.1016/j.amjcard.2013.01.287
Abbate, A. et al. Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment-elevation myocardial infarction. J. Am. Heart Assoc. 9, e014941 (2020).
pubmed: 32122219 pmcid: 7335541 doi: 10.1161/JAHA.119.014941
Kleveland, O. et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur. Heart J. 37, 2406–2413 (2016).
pubmed: 27161611 doi: 10.1093/eurheartj/ehw171
Kleveland, O. et al. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. Int. J. Cardiol. 271, 1–7 (2018).
pubmed: 29961572 doi: 10.1016/j.ijcard.2018.04.136
Carroll, M. B., Haller, C. & Smith, C. Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol. Int. 38, 59–66 (2018).
pubmed: 29067495 doi: 10.1007/s00296-017-3842-y
Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845–1855 (2021).
pubmed: 33858620 doi: 10.1016/j.jacc.2021.02.049
Kunkel, J. B. et al. Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development – rationale and design of the DOBERMANN trial [abstract zuad036.131]. Eur. Heart J. Acute Cardiovasc. Care 12 (Suppl. 1), i193–i194 (2023).
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT05350592 (2024).
Ridker, P. M. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc. Res. 117, e138–e140 (2021).
pubmed: 34352102 pmcid: 8861265 doi: 10.1093/cvr/cvab231
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT06118281 (2024).
Zhao, T. X. et al. Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study. Cardiovasc. Res. 118, 872–882 (2022).
pubmed: 33783498 doi: 10.1093/cvr/cvab113
Zhao, T. X. et al. Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease. NEJM Evid. 1, EVIDoa2100009 (2022).
pubmed: 38319239 doi: 10.1056/EVIDoa2100009
US National Library of Medicine. ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT04241601 (2024).
Borén, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41, 2313–2330 (2020).
pubmed: 32052833 pmcid: 7308544 doi: 10.1093/eurheartj/ehz962
Moore, K. J., Sheedy, F. J. & Fisher, E. A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13, 709–721 (2013).
doi: 10.1038/nri3520
Binder, C. J., Papac-Milicevic, N. & Witztum, J. L. Innate sensing of oxidation-specific epitopes in health and disease. Nat. Rev. Immunol. 16, 485–497 (2016).
pubmed: 27346802 pmcid: 7097710 doi: 10.1038/nri.2016.63
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
pubmed: 14561795 doi: 10.1056/NEJMoa021933
Hung, T. et al. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 350, 455–459 (2015).
pubmed: 26382853 pmcid: 4691329 doi: 10.1126/science.aac7442
Kudo, T. et al. Regulation of NETosis and inflammation by cyclophilin D in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 75, 71–83 (2023).
pubmed: 35905194 doi: 10.1002/art.42314
Müller-Calleja, N. et al. Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science 371, eabc0956 (2021).
pubmed: 33707237 pmcid: 9014225 doi: 10.1126/science.abc0956
Schreiber, K. et al. Antiphospholipid syndrome. Nat. Rev. Dis. Prim. 4, 17103 (2018).
pubmed: 29321641 doi: 10.1038/nrdp.2017.103
Pagano, S. et al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J. Intern. Med. 272, 344–357 (2012).
pubmed: 22329401 doi: 10.1111/j.1365-2796.2012.02530.x
Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Prim. 6, 71 (2020).
pubmed: 32855422 doi: 10.1038/s41572-020-0204-y
van Delft, M. A. M. & Huizinga, T. W. J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 110, 102392 (2020).
pubmed: 31911013 doi: 10.1016/j.jaut.2019.102392
Vander Cruyssen, B. et al. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun. Rev. 4, 468–474 (2005).
doi: 10.1016/j.autrev.2005.04.018
Anquetil, F., Clavel, C., Offer, G., Serre, G. & Sebbag, M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J. Immunol. 194, 3664–3674 (2015).
pubmed: 25769920 doi: 10.4049/jimmunol.1402334
Suurmond, J. & Diamond, B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J. Clin. Invest. 125, 2194–2202 (2015).
pubmed: 25938780 pmcid: 4497746 doi: 10.1172/JCI78084

Auteurs

Florentina Porsch (F)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
ORCID: 0000-0002-2633-6632

Christoph J Binder (CJ)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. christoph.binder@meduniwien.ac.at.
ORCID: 0000-0001-8313-7050

Classifications MeSH